Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice

Andrew L. Feldman, Nicholas P. Restifo, H. Richard Alexander, David L. Bartlett, Patrick Hwu, Prem Seth, Steven K. Libutti

Research output: Contribution to journalArticle

127 Scopus citations

Abstract

Gene therapy represents a possible alternative to the chronic delivery of recombinant antiangiogenic proteins to cancer patients. Inducing normal host tissues to produce high circulating levels of these proteins may be more effective than targeting antiangiogenic genes to tumor tissue specifically. Previously reported gene therapy approaches in mice have achieved peak circulating endostatin levels of 8-33 ng/ml. Here we report plasma endostatin levels of 1770 ng/ml after administration of a recombinant adenovirus. Growth of MC38 adenocarcinoma, which is relatively resistant to adenoviral infection, was inhibited by 40%. These findings encourage gene delivery approaches that use the host as a 'factory' to produce high circulating levels of antiangiogenic agents.

Original languageEnglish (US)
Pages (from-to)1503-1506
Number of pages4
JournalCancer research
Volume60
Issue number6
StatePublished - Mar 15 2000

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice'. Together they form a unique fingerprint.

Cite this